Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies
Emma Guttman‐Yassky, Jacob P. Thyssen, Jonathan I. Silverberg, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 151, Iss. 1, pp. 172-181
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Type 2 chronic inflammatory diseases: targets, therapies and unmet needs
Pavel Kolkhir, Cezmi A. Akdiş, Mübeccel Akdiş, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 9, pp. 743-767
Closed Access | Times Cited: 68
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Svenja Müller, Laura Maintz, Thomas Bieber
Allergy (2024) Vol. 79, Iss. 6, pp. 1501-1515
Open Access | Times Cited: 49
Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence
Masahiro Kamata, Yayoi Tada
JID Innovations (2023) Vol. 3, Iss. 3, pp. 100195-100195
Open Access | Times Cited: 44
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Brett King, Jennifer Soung, Christos Tziotzios, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 2, pp. 299-314
Open Access | Times Cited: 20
Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors
Richard W. Kim, Megan Lam, Katrina Abuabara, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 2, pp. 179-193
Closed Access | Times Cited: 19
Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm
Carlo Alberto Maronese, Chiara Moltrasio, Giovanni Genovese, et al.
Expert Review of Clinical Immunology (2023) Vol. 20, Iss. 5, pp. 525-545
Closed Access | Times Cited: 27
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 15
Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study
Thierry Passeron, Khaled Ezzedine, Iltefat Hamzavi, et al.
EClinicalMedicine (2024) Vol. 73, pp. 102655-102655
Open Access | Times Cited: 12
Infections in Patients with Atopic Dermatitis and the Influence of Treatment
Maddalena Napolitano, Maria Esposito, Maria Concetta Fargnoli, et al.
American Journal of Clinical Dermatology (2025)
Open Access | Times Cited: 1
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement
Victoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases (2025)
Open Access | Times Cited: 1
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs
Pablo A. Olivera, Juan S. Lasa, Giovanni Peretto, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 57, Iss. 11, pp. 1231-1248
Open Access | Times Cited: 20
Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 8, pp. 1983-2038
Open Access | Times Cited: 8
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
Celeste M. Boesjes, Lian F. van der Gang, Nicolaas P. A. Zuithoff, et al.
Acta Dermato Venereologica (2023) Vol. 103, pp. adv00872-adv00872
Open Access | Times Cited: 14
Background factors predicting the occurrence of herpes zoster in atopic dermatitis patients treated with upadacitinib
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
The Journal of Dermatology (2023) Vol. 50, Iss. 10, pp. 1301-1312
Closed Access | Times Cited: 14
Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis
Elena Pezzolo, Michela Ortoncelli, Silvia Ferrucci, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 553-553
Open Access | Times Cited: 5
Updates in atopic dermatitis for the primary care physician: A review of advances in the understanding and treatment of atopic dermatitis
Zi-Yi Choo, Stephanie Mehlis, Joel C. Joyce
Disease-a-Month (2024) Vol. 70, Iss. 4, pp. 101687-101687
Closed Access | Times Cited: 4
Prurigo Nodularis: Pathogenesis and the Horizon of Potential Therapeutics
Hwa Jung Yook, Ji Hyun Lee
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 10, pp. 5164-5164
Open Access | Times Cited: 4
Off-label use of JAK1 inhibitor upadacitinib in dermatology
Tianyi Zhang, Yueping Zeng
Archives of Dermatological Research (2025) Vol. 317, Iss. 1
Closed Access
Successful Treatment of Severe Pediatric Atopic Dermatitis with Upadacitinib
Lee Tyan Shin, Henrietta Albela, Deirdre Ooi, et al.
Indian Journal of Dermatology (2025)
Open Access
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update
Peter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
JAK inhibitors and the risk of infection: a meta-analysis
Hong Ran, Huan Liu, Wenting Xu, et al.
Archives of Dermatological Research (2025) Vol. 317, Iss. 1
Closed Access
Spanish Working Group in Crohn’s Disease and Ulcerative Colitis (GETECCU) position paper on cardiovascular disease in patients with inflammatory bowel disease
Ignacio Marín‐Jiménez, Daniel Carpio, Vicent Hernández, et al.
Gastroenterología y Hepatología (English Edition) (2025), pp. 502314-502314
Closed Access
Potential role of upadacitinib in cytomegalovirus colitis recurrence
Kaito Tsujinaka, Marina Kannno, Atsushi Ogawa, et al.
European Journal of Case Reports in Internal Medicine (2025)
Open Access
Bullous Central Serous Chorioretinopathy Associated With JAK Inhibitor Use
Warren Apel, Ye Li
Journal of VitreoRetinal Diseases (2025)
Closed Access
Upadacitinib for moderate‐to‐severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics
Jacob P. Thyssen, Diamant Thaçi, Thomas Bieber, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 9, pp. 1871-1880
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top